Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 5
1984 2
1985 3
1986 2
1987 4
1988 3
1990 1
1997 1
2001 1
2004 1
2005 1
2006 4
2007 4
2008 6
2009 10
2010 12
2011 13
2012 8
2013 21
2014 35
2015 35
2016 36
2017 38
2018 25
2019 28
2020 32
2021 41
2022 47
2023 27
2024 23

Text availability

Article attribute

Article type

Publication date

Search Results

399 results

Results by year

Filters applied: . Clear all
Page 1
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.
Kalakonda N, Maerevoet M, Cavallo F, Follows G, Goy A, Vermaat JSP, Casasnovas O, Hamad N, Zijlstra JM, Bakhshi S, Bouabdallah R, Choquet S, Gurion R, Hill B, Jaeger U, Sancho JM, Schuster M, Thieblemont C, De la Cruz F, Egyed M, Mishra S, Offner F, Vassilakopoulos TP, Warzocha K, McCarthy D, Ma X, Corona K, Saint-Martin JR, Chang H, Landesman Y, Joshi A, Wang H, Shah J, Shacham S, Kauffman M, Van Den Neste E, Canales MA. Kalakonda N, et al. Lancet Haematol. 2020 Jul;7(7):e511-e522. doi: 10.1016/S2352-3026(20)30120-4. Lancet Haematol. 2020. PMID: 32589977 Free article. Clinical Trial.
BACKGROUND: Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer with a median overall survival of less than 6 months. ...Germinal centre B-cell or non-germinal centre B-cell tumour subtype and double or triple expressor status …
BACKGROUND: Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer with a median overall survival of le …
RNA binding protein IGF2BP1 synergizes with ETV6-RUNX1 to drive oncogenic signaling in B-cell Acute Lymphoblastic Leukemia.
Sharma G, Tran TM, Bansal I, Beg MS, Bhardwaj R, Bassi J, Tan Y, Jaiswal AK, Tso C, Jain A, Singh J, Chattopadhyay P, Singh A, Chopra A, Bakhshi S, Casero D, Rao DS, Palanichamy JK. Sharma G, et al. J Exp Clin Cancer Res. 2023 Sep 5;42(1):231. doi: 10.1186/s13046-023-02810-1. J Exp Clin Cancer Res. 2023. PMID: 37670323 Free PMC article.
These pathways were also dysregulated in primary ETV6::RUNX1 positive B-ALL patient samples from our center as well as in public B-ALL patient datasets. ...CONCLUSION: Our data suggest a combined impact of the ETV6::RUNX1 fusion protein and RNA binding protein, IGF2 …
These pathways were also dysregulated in primary ETV6::RUNX1 positive B-ALL patient samples from our center as well as in public B …
Genetic and epigenetic determinants of diffuse large B-cell lymphoma.
Bakhshi TJ, Georgel PT. Bakhshi TJ, et al. Blood Cancer J. 2020 Dec 4;10(12):123. doi: 10.1038/s41408-020-00389-w. Blood Cancer J. 2020. PMID: 33277464 Free PMC article. Review.
Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma and is notorious for its heterogeneity, aggressive nature, and the frequent development of resistance and/or relapse after treatment with standard chemotherapy. ...
Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma and is notorious for its heterogeneity, aggressive nature, …
Genera of phytopathogenic fungi: GOPHY 4.
Chen Q, Bakhshi M, Balci Y, Broders KD, Cheewangkoon R, Chen SF, Fan XL, Gramaje D, Halleen F, Jung MH, Jiang N, Jung T, Májek T, Marincowitz S, Milenković I, Mostert L, Nakashima C, Nurul Faziha I, Pan M, Raza M, Scanu B, Spies CFJ, Suhaizan L, Suzuki H, Tian CM, Tomšovský M, Úrbez-Torres JR, Wang W, Wingfield BD, Wingfield MJ, Yang Q, Yang X, Zare R, Zhao P, Groenewald JZ, Cai L, Crous PW. Chen Q, et al. Stud Mycol. 2022 Jul;101:417-564. doi: 10.3114/sim.2022.101.06. Epub 2022 Jun 2. Stud Mycol. 2022. PMID: 36059898 Free PMC article.
Nakash.; New combinations: Heterophaeomoniella pinifoliorum (Hyang B. Lee et al.) L. Mostert, C.F.J. Spies, Halleen & Gramaje, Pseudocercospora pruni-grayanae (Sawada) C. ...Matsumoto, Phaeoisariopsis pruni-grayanae Sawada, Pseudocercospora symploci Katsuki & Tak. …
Nakash.; New combinations: Heterophaeomoniella pinifoliorum (Hyang B. Lee et al.) L. Mostert, C.F.J. Spies, Halleen & Gramaje, Ps …
Prognostic relevance of surface expression of cytokine receptor-like factor 2 in pediatric B-lineage acute lymphoblastic leukemia.
Singh J, Benjamin M, Pandey AK, Kumari S, Ali MS, Palanichamy JK, Bakhshi S, Singh A, Pushpam D, Kumar A, Seth R, Singh I, Tanwar P, Singh AR, Sharma G, Arora M, Chopra A. Singh J, et al. Am J Cancer Res. 2023 Jun 15;13(6):2452-2470. eCollection 2023. Am J Cancer Res. 2023. PMID: 37424808 Free PMC article.
Overexpression of cytokine receptor-like factor 2 (CRLF2) resulting from its genomic rearrangement is the most frequent genetic alteration found in Philadelphia chromosome-like (Ph-like) B-cell acute lymphoblastic leukemia (B-ALL), a high-risk leukemia. Detection of …
Overexpression of cytokine receptor-like factor 2 (CRLF2) resulting from its genomic rearrangement is the most frequent genetic alteration f …
Management of Hepatoblastoma: ICMR Consensus Document.
Agarwala S, Gupta A, Bansal D, Vora T, Prasad M, Arora B, Kapoor G, Chinnaswamy G, Radhakrishnan V, Laskar S, Kaur T, Dhaliwal RS, Rath GK, Bakhshi S. Agarwala S, et al. Indian J Pediatr. 2017 Jun;84(6):456-464. doi: 10.1007/s12098-017-2301-9. Epub 2017 Mar 29. Indian J Pediatr. 2017. PMID: 28353129 Review.
Fusarium and allied fusarioid taxa (FUSA). 1.
Crous PW, Sandoval-Denis M, Costa MM, Groenewald JZ, van Iperen AL, Starink-Willemse M, Hernández-Restrepo M, Kandemir H, Ulaszewski B, de Boer W, Abdel-Azeem AM, Abdollahzadeh J, Akulov A, Bakhshi M, Bezerra JDP, Bhunjun CS, Câmara MPS, Chaverri P, Vieira WAS, Decock CA, Gaya E, Gené J, Guarro J, Gramaje D, Grube M, Gupta VK, Guarnaccia V, Hill R, Hirooka Y, Hyde KD, Jayawardena RS, Jeewon R, Jurjević Ž, Korsten L, Lamprecht SC, Lombard L, Maharachchikumbura SSN, Polizzi G, Rajeshkumar KC, Salgado-Salazar C, Shang QJ, Shivas RG, Summerbell RC, Sun GY, Swart WJ, Tan YP, Vizzini A, Xia JW, Zare R, González CD, Iturriaga T, Savary O, Coton M, Coton E, Jany JL, Liu C, Zeng ZQ, Zhuang WY, Yu ZH, Thines M. Crous PW, et al. Fungal Syst Evol. 2022 Jun;9:161-200. doi: 10.3114/fuse.2022.09.08. Epub 2022 Jun 23. Fungal Syst Evol. 2022. PMID: 35978986 Free PMC article.
Citation: Crous PW, Sandoval-Denis M, Costa MM, Groenewald JZ, van Iperen AL, Starink-Willemse M, Hernandez-Restrepo M, Kandemir H, Ulaszewski B, de Boer W, Abdel-Azeem AM, Abdollahzadeh J, Akulov A, Bakhshi M, Bezerra JDP, Bhunjun CS, Camara MPS, Chaverri P, Vieira …
Citation: Crous PW, Sandoval-Denis M, Costa MM, Groenewald JZ, van Iperen AL, Starink-Willemse M, Hernandez-Restrepo M, Kandemir H, Ulaszews …
Metronomic therapy in pediatric oncology: A snapshot.
Pramanik R, Bakhshi S. Pramanik R, et al. Pediatr Blood Cancer. 2019 Sep;66(9):e27811. doi: 10.1002/pbc.27811. Epub 2019 Jun 17. Pediatr Blood Cancer. 2019. PMID: 31207063 Review.
Management of Neuroblastoma: ICMR Consensus Document.
Bansal D, Totadri S, Chinnaswamy G, Agarwala S, Vora T, Arora B, Prasad M, Kapoor G, Radhakrishnan V, Laskar S, Kaur T, Rath GK, Bakhshi S. Bansal D, et al. Indian J Pediatr. 2017 Jun;84(6):446-455. doi: 10.1007/s12098-017-2298-0. Epub 2017 Apr 3. Indian J Pediatr. 2017. PMID: 28367616 Review.
399 results